Decrease in accumulation of ultrasound contrast microbubbles in non‐alcoholic steatohepatitis
- 15 June 2007
- journal article
- Published by Wiley in Hepatology Research
- Vol. 37 (9) , 722-730
Abstract
Aim: Non‐alcoholic steatohepatitis (NASH) is one of the representative liver diseases in developed countries. Diagnosis of NASH is dependent on histological findings from liver biopsy.Methods: The usefulness of contrast ultrasound with Levovist for diagnosis of NASH is described. 2.5 g of ultrasound contrast agent Levovist was injected intravenously. The liver was scanned at 5, 10, 15, 20, 30, 40 and 50 min and changes in microbubble accumulation were evaluated. The signal intensity from regions of interest (ROI) on the contrast images was measured and estimated using time intensity curves (TICs). Twenty‐one patients with NASH, 33 with non‐alcoholic fatty liver disease (NAFLD) and 10 healthy volunteers (HV) were studied. The signal intensity was measured quantitatively at 5 and 20 min after injection.Results: There was a statistically significant decrease in NASH, when compared with NAFLD and HV groups. These changes in signal intensity were not correlated to the degree of fibrosis and steatosis in histological study. The sensitivity, specificity and overall accuracy obtained from the receiver operating characteristic (ROC) curve were 100% when the cut‐off value was set at 43.6 of signal intensity at 20 min.Conclusion: The Levovist contrast study is a useful screening examination which picks up NASH among fatty liver patients.Keywords
This publication has 44 references indexed in Scilit:
- Dynamic US contrast study of the liver: Vascular and delayed parenchymal phaseHepatology Research, 2007
- Ultrasound contrast agent, Levovist microbubbles are phagocytosed by Kupffer cells—In vitro and in vivo studiesHepatology Research, 2006
- Usefulness of contrast-enhanced ultrasonography with a new contrast mode, Agent Detection Imaging, in evaluating therapeutic response in hepatocellular carcinoma treated with radio-frequency ablation therapyHepatology Research, 2004
- Nonalcoholic SteatohepatitisMayo Clinic Proceedings, 2000
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- Cryptogenic Cirrhosis: Clinical Characterization and Risk Factors for Underlying DiseaseHepatology, 1999
- Role of Kupffer Cell‐Derived Reactive Oxygen Intermediates in Alcoholic Liver Disease in Rats In VivoAlcohol, Clinical and Experimental Research, 1996
- Lipid deposition in kupffer cells after parenteral fat nutrition in rats: A biochemical and ultrastructural studyIntensive Care Medicine, 1996
- Sensitization of Hepatic Lipocytes by High–Fat Diet to Stimulatory Effects of Kupffer Cell–Derived Factors: Implication in Alcoholic Liver FibrogenesisHepatology, 1990
- Ultrasonographical Diagnosis of Fatty Liver: Significance of the Liver-Kidney ContrastThe Tohoku Journal of Experimental Medicine, 1983